Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
How are you integrating Prostox into your practice for prostate patients deciding between SBRT and hypofractionation?
Related Questions
What is the rationale for the recent change in the NCCN criteria for very high risk prostate cancer?
What is your preferred approach in a patient unable to fill their bladder during prostate radiotherapy?
How do you approach ADT in patients with high risk prostate cancer who have risk factors for VTE, such as Factor V Leiden?
In a patient with a synchronous prostate cancer and non-invasive urothelial carcinoma limited to the prostatic urethra is complete TUR and definitive prostate dose to standard prostate fields adequate treatment?
How do you manage malignancies in patients with Birt-Hogg-Dubé syndrome (BHD)? Is there concern for increased radiosensitivity?
Would you ever re-irradiate the groin/inguinal region?
How do you talk to patients with intermediate-risk prostate cancer deciding between LDR brachytherapy (monotherapy) vs HDR mono vs SBRT vs EBRT, in terms of the comparative side effect profile of each approach?
How do you manage prostatic adenocarcinoma after a subtotal resection?
What are your top takeaways in GU Cancers from ASCO 2025?
Given the PATRIOT trial and hypo-FLAME 2.0, do you consider once-a-week prostate SBRT instead of every other day?
